We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
- Authors
Schultz, Kirk R; Bowman, W Paul; Aledo, Alexander; Slayton, William B; Sather, Harland; Devidas, Meenakshi; Wang, Chenguang; Davies, Stella M; Gaynon, Paul S; Trigg, Michael; Rutledge, Robert; Burden, Laura; Jorstad, Dean; Carroll, Andrew; Heerema, Nyla A; Winick, Naomi; Borowitz, Michael J; Hunger, Stephen P; Carroll, William L; Camitta, Bruce
- Abstract
Imatinib mesylate is a targeted agent that may be used against Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), one of the highest risk pediatric ALL groups.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 31, p5175
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.21.2514